Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
Renal Cancer Treatment: A Review of the LiteratureLuca Gattinoni, Emilio Bajetta, Agata Laudani et al.|Tumori Journal|2003Cited by 17
Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.Marina Elena Cazzaniga, P. Pronzato, Francesco Schettini et al.|Journal of Clinical Oncology|2019Cited by 0
Abstract P5-07-10: Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA studyMarina Elena Cazzaniga, Sabino De Placido, Alessia D’Alonzo et al.|Cancer Research|2020Cited by 0